The egfr gene codes for a specialised protein called a receptor located on the surface of cells. Egfr mutation test v2 is a real time pcr test for the qualitative detection of defined mutations of the epidermal growth factor receptor egfr gene in dna derived from formalinfixed paraffinembedded tumor tissue ffpet from nonsmall cell lung cancer nsclc patients. Tumour content ratio matters for detecting epidermal growth factor. May 11, 2015 the cobas 4800 system menu for oncology in the u. The cobas egfr mutation test v2 was used for the detection of egfr.
The reliability of the cobas egfr assay to detect epidermal growth factor receptor egfr mutations in nonsmallcell lung cancer nsclc as an in vitro diagnostic test was compared with 3 laboratorydeveloped tests ldts. Roche expands indication for cobas egfr mutation test v2 as. Apr 05, 2014 cobas egfr mutation test conference media design. The identification of other clinically relevant egfr mutations has been validated by phenopath laboratories. The cobas egfr mutation test v2 is a realtime pcr test that identifies 42 mutations in exons 1821, including l858r, exon 19 deletions, l861q and the tki.
Epidermal growth factor receptor egfr is the most important driver gene. Possible application of circulating free tumor dna in nonsmall cell. The cobas egfr mutation test v2 for use with plasma is further indicated for the semiquantitative measurement of mutations in exons 18, 19, 20, and 21 of the egfr gene from serial collections of human plasma as an aid in the management of nsclc cancer patients. Jun 02, 2016 the fda approved the cobas egfr mutation test v2 to detect gene mutation associated with nonsmall cell lung cancer. Roche roche launches the cobas egfr mutation test v2 for.
Phenopath is pleased to offer the roche cobas egfr mutation test v2, the only fdaapproved ivd assay for the detection of t790m, exon 19 deletion, and l858r egfr mutations in dna isolated from formalin fixed paraffin embedded tumor tissue ffpe or in cellfreecirculating tumor dna from plasma. Request pdf profile of the roche cobas egfr mutation test v2 for nonsmall cell lung cancer introduction. Egfrpositive lung cancer refers to lung cancers that test positive for an egfr mutation. The cobas egfr mutation test v2 is a real time pcr test for the qualitative detection of defined mutations of the epidermal growth factor receptor egfr gene in dna derived from formalinfixed paraffinembedded tumor tissue ffpet from nonsmall cell lung cancer nsclc patients.
Fda approves cobas egfr mutation test v2 for patients with nsclc. Comparison of molecular testing methods for the detection of egfr. Fda approves roche cobas egfr mutation test as cdx with. Defined egfr mutations are detected using dna isolated from formalinfixed paraffinembedded tumor tissue ffpet or circulatingfree tumor dna cfdna from plasma derived from edta anticoagulated peripheral whole blood. Information around testing technologies including egfr mutation testing kits. Roche receives fda approval for cobas egfr mutation test v2. The cobas egfr mutation test v2 is a realtime pcr test that identifies 42 mutations in exons 18, 19, 20 and 21 of the epidermal growth factor receptor egfr gene, including the t790m resistant mutation. Roche receives fda approval for cobas egfr mutation test v2 as a companion diagnostic for nonsmall cell lung cancer therapies nextgeneration test using tissue samples is approved for use as a. Profile of the roche cobas egfr mutation test v2 for nonsmall. New test is the first to be validated for use of either sample type in a single test. Analytical performance of the cobas egfr mutation assay for.
Patients who are negative for t790m by this test should be reflexed to routine biopsy and testing for egfr mutations with the ffpe sample type4. The cobas egfr mutation test v2 is a realtime pcr test for the qualitative detection of 42 defined mutations of the egfr gene in exons 1821, including l858r, exon 19 deletions, and t790m mutations. To ensure that the egfr mutation testing process is reliable and consistent, and to ensure any driver mutations are characterised, it is essential to build quality assurance into every step of the procedure. Mar 14, 2017 new test is the first to be validated for use of either sample type in a single test. In this study, we compared the performance of the cobas egfr mutation test cobas egfr assay and the therascreen egfr rgq pcr kit therascreen egfr assay for use as an in vitro. Roche receives fda approval for cobas kras mutation test. The cobas pik3ca mutation test is a realtime pcr test for the qualitative detection and identification of mutations in exons 1, 4, 7, 9 and 20 of the phosphatidylinositol3kinase catalytic subunit alpha isoform pi3kca gene in dna derived from formalinfixed paraffinembedded tissue ffpet.
Cobas egfr mutation test v2 brand, cobas egfr mutation test. Fda approves cobas egfr mutation test v2 for patients with. Rhhby today announced the commercial availability in countries that. This information is useful in guiding treatment of nonsmall cell lung cancer. Jul 31, 2015 roche submitted the cobas egfr mutation test v2 for premarket approval pma to the us food and drug administration fda, as a companion diagnostic test for azd9291, an astrazeneca investigational therapy for nonsmall cell lung cancer nsclc patients with an acquired resistant mutation. Roche launches the cobas egfr mutation test v2 for use. Detection of epidermal growth factor receptor gene t790m. The cobas egfr mutation test v2 is a realtime pcr test for the qualitative detection of defined mutations of the epidermal growth factor receptor egfr gene in nonsmall cell lung cancer nsclc patients. The cobas egfr mutation test v2 is a real time pcr test for the qualitative detection of defined mutations of the epidermal growth factor receptor egfr gene in non small cell lung cancer nsclc patients. Detection of egfr mutations and analysis of cobas test sensitivity. The key benefits of testing with plasma is that it involves a noninvasive procedure for collecting biopsy from the patient and it can be sampled as frequently as.
For instance, epidermal growth factor receptor egfr mutations, anaplastic. Laval, qc, march 14, 2017 cnw telbec roche diagnostics canada announced that health canada has approved the cobas egfr mutation test v2, the first oncology assay from roche that utilizes either plasma or tumor tissue as a sample. Sep 29, 2016 fda grants roche label extension for the cobas egfr mutation test v2 for use with plasma as a companion diagnostic for tagrisso read this article along with other careers information, tips and advice on biospace. The test a bloodbased companion diagnostic for the cancer drug erlotinib. Among the 35 egfr mutations detected via the direct sequencing of 73. The test is intended to aid in identifying patients.
The pcrbased test, which detects mutations in codons 12. Roche received ce mark approval for its cobas kras mutation test to predict response to anti epidermal growth factor receptor egfr therapies in colorectal cancer patients. Frequency and significance of epidermal growth factor receptor. Roche launches the cobas egfr mutation test v2 for use with. The cobas egfr mutation test v2 is a realtime pcr test that identifies 42 mutations in exons 1821, including l858r, exon 19 deletions, l861q and the. Defined egfr mutations are detected using dna isolated from formalinfixed paraffinembedded tumor tissue ffpet or circulatingfree. The cobas egfr mutation test is a companion diagnostic for osimertinib it is unclear if the test can detect egfr t790m mutations in cytology samples. The fda approved the cobas egfr mutation test v2 to detect gene mutation associated with nonsmall cell lung cancer. Nov, 2015 new york genomeweb the us food and drug administration has approved roches cobas egfr mutation test v2 as a companion diagnostic alongside astrazenecas tagrisso osimertinib for nonsmall cell lung cancer patients, roche said today. About roche headquartered in basel, switzerland, roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Tumour tissues were manually dissected with a scalpel under a. Detection of egfr gene mutations is essential in choosing nsclc treatments.
Please use one of the following formats to cite this article in your essay, paper or report. Profile of the roche cobas egfr mutation test v2 for nonsmall cell lung cancer. Egfr is a short name for the epidermal growth factor receptor gene. The roche cobas egfr mutation test v2 is an fdaapproved assay for identifying egfr t790m, exon 19 deletions, and exon 21 l858r substitution mutations in circulating tumor dna obtained from patients with nonsmall cell lung carcinoma. The cobas egfr mutation test v2 for use with plasma test is intended to be used to initially screen patients with metastatic nsclc for egfr mutations. Roche launches the cobas egfr mutation test v2 for use with either plasma or tumour tissue samples. Fda grants roche label extension for the cobas egfr mutation. Usa and the cobas egfr mutation test v2 roche diagnostics.
The cobas egfr mutation plasma test v2 is a realtime pcr test for the qualitative detection and identification of mutations in exons 18, 19, 20, and 21 of the epidermal growth factor receptor egfr gene in dna derived from plasma from nonsmall cell lung cancer nsclc patients. The cobas egfr test is based on two major processes. Profile of the roche cobas egfr mutation test v2 for non. The cobas egfr mutation test is based on two major processes. Egfr mutation test v2 00875197005448 no description. Egfr mutation testing at diagnossi and disease progression, types of testing technologies available, and how to interpret results. Fda approved a pma from roche for a bloodbased version of its cobas egfr mutation test v2 as a companion diagnostic for tagrisso osimertinib from astrazeneca to treat egfr t790m mutation positive, metastatic nonsmall cell lung. Roches cobas egfr mutation testcourtesy of roche in one of many wins for 20.
Roche receives approval in japan for the cobas egfr mutation. The fdaapproved cobas 4800 egfrv2 mutation test is a realtime pcr assay designed for the qualitative detection of mutations involving exons 18, 19, 20 and 21 of the egfr oncogene in nonsmall cell lung cancer nsclc patients. The egfr mutation testing landscape is manifold and includes both screening and targeted methods, each with their own pros and cons. Egfr mutation testing lab tests online au blood test. For manual sample preparation, ffpet specimens are processed using the cobas dna sample preparation kit and the cobas z 480 analyzer is used for.
Sep 29, 2016 new york genomeweb the us food and drug administration has expanded the labeling for roches cobas egfr mutation test v2 as a companion diagnostic that can analyze plasma samples from nonsmall cell lung cancer patients considering treatment with astrazenecas tagrisso osimertinib. Epidermal growth factor receptor egfr is a protein that is present on the surface of both normal cells and cancer cells, including lung cancer cells. The cobas egfr mutation test kit aspcr test, allelespecific pcr test, roche molecular systems, inc. Sep 28, 2015 roche launches the cobas egfr mutation test v2 for use with either plasma or tumour tissue samples new test is the first to be validated for use of either sample type in a single test roche six. Accuracy of the cobas egfr mutation assay in nonsmallcell. Guide to detecting epidermal growth factor receptor egfr ncbi. Jun 02, 2016 the agreement between the cobas egfr mutation test v2 in plasma and the cobasegfr mutation test v1 in tissue was evaluated for detection of egfr mutations ex.
Fda expands label for roche cobas egfr companion diagnostic. The discovery of driver mutations in nonsmall cell lung cancer nsclc has led to the development of genomebased personalized. Cobas egfr is also the first test of its kind targeted toward the specific egfr mutations. This test detects mutations in the egfr gene in cancer tissue. Roche receives approval in japan for the cobas egfr mutation test v2 new test includes expanded mutation coverage to detect egfr mutations in nonsmall cell lung cancer patients.
434 1399 969 271 826 468 723 180 415 1248 1220 35 143 803 172 1463 1087 1590 255 1002 199 1470 1118 807 1183 723 1142 1474 175 138 907 1494 921 622 1355 738 578